Blog
RSS FeedPosted by Michael Wonder on 03 Jul 2022
Rare blood cancer drug Brukinsa to be listed for the first time on Pharmaceutical Benefits Scheme
1 July 2022 - Graeme Anderson had just finished seven days of night shift when he first noticed something didn’t feel ...
Posted by Michael Wonder on 03 Jul 2022
NHS saves £1.2 billion on medicines over three years
1 July 2022 - The NHS has saved taxpayers £1.2 billion in just three years, while securing cutting-edge treatments for ...
Posted by Michael Wonder on 01 Jul 2022
Public Summary Documents – March 2022 PBAC meeting
1 July 2022 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the March 2022 PBAC ...
Posted by Michael Wonder on 01 Jul 2022
New PBS listings from 1 July 2022
1 July 2022 - Vitrakvi (larotrectinib) will list for the first time for the treatment of adult and paediatric patients with ...
Posted by Michael Wonder on 30 Jun 2022
Australian Medical Association prescribes new regulator to save private health system
30 June 2022 - The Australian Medical Association is calling for a new regulator to oversee the private health system, ...
Posted by Michael Wonder on 30 Jun 2022
PBS listing for ‘Australian success story’ blood cancer drug
1 July 2022 - A pill that removes the need for chemotherapy for some cancer sufferers has been put on ...
Posted by Michael Wonder on 30 Jun 2022
New strategic agreements with the medicines industry – PBS website updates
1 July 2022 - Amendments made by the National Health Amendment (Enhancing the Pharmaceutical Benefits Scheme) Act 2021 give effect to ...
Posted by Michael Wonder on 30 Jun 2022
Schedule of Pharmaceutical Benefits - 1 July 2022
1 July 2022 - The July 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 30 Jun 2022
Update to continued dispensing arrangements
30 June 2022 - From 1 July 2022, on-going continued dispensing arrangements have been expanded to include additional medicines groups to ...
Posted by Michael Wonder on 30 Jun 2022
Zanubrutinib for the treatment of adults with Waldenström’s macroglobulinaemia
29 June 2022 - NICE has published a second appraisal consultation document on the use of zanubrutinib for the treatment ...
Posted by Michael Wonder on 29 Jun 2022
Accuretic supply issue, almost 36,000 New Zealanders taking the blood pressure medicine will need to change treatments
30 June 2022 - PHARMAC has updated health care professionals that supply of quinapril with hydrochlorothiazide (branded as Accuretic), from supplier ...
Posted by Michael Wonder on 29 Jun 2022
NICE publishes its 800th technology assessment
29 June 2022 - TAs 799 and 800 are for the same technology. ...
Posted by Michael Wonder on 28 Jun 2022
The Innovative Medicines Fund - good news for patients but has an opportunity been missed to be more ambitious?
27 June 2022 - NHS England and Improvement has announced the launch of the Innovative Medicines Fund. The ABPI’s Director ...
Posted by Michael Wonder on 27 Jun 2022
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy
23 June 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 27 Jun 2022
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma
23 June 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...